Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells

Journal of Biological Chemistry

Volumn 292, Issue 33, 2017, Pages 13551-13564

  Tan, Sheng ^a,b   Ding, Keshuo ^a,c   Chong, Qing Yun ^d   Zhao, Junsong ^a   Liu, Yuan ^a   Shao, Yunying ^a   Zhang, Yuanyuan ^a   Yu, Qing ^a,b   Xiong, Zirui ^a   Zhang, Weijie ^a,b   Zhang, Min ^a,b   Li, Gaopeng ^a,b   Li, Xiaoni ^a,b   Kong, Xiangjun ^a,b   Ahmad, Akhlaq ^a   Wu, Zhengsheng ^c   Wu, Qiang ^c   Zhao, Xiaodong ^f   Lobie, Peter E ^a,d,e,g   Zhu, Tao ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

^g TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DISEASES; ELECTRIC RESISTANCE; TRANSCRIPTION;

BREAST CANCER; BREAST CANCER CELLS; ESTROGEN RECEPTOR; POLYADENYLATION; POST-TRANSCRIPTIONAL; POST-TRANSCRIPTIONAL REGULATIONS; RECEPTOR TYROSINE KINASE; RNA-BINDING PROTEIN;

CYTOLOGY;

CLEAVAGE STIMULATION FACTOR; CLEAVAGE STIMULATION FACTOR 2; ELAV LIKE PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 26A; MICRORNA 26B; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CSTF2T PROTEIN, HUMAN; ELAVL1 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MIRN26A MICRORNA, HUMAN; RNA; RNA BINDING PROTEIN; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG RESISTANCE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE INACTIVATION; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSCRIPTION REGULATION; UPREGULATION; AGONISTS; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; RNA INTERFERENCE; RNA STABILITY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ELAV-LIKE PROTEIN 1; FEMALE; HUMANS; MICRORNAS; MUTATION; NEOPLASM PROTEINS; POLYADENYLATION; RECEPTOR, ERBB-2; RESPONSE ELEMENTS; RNA INTERFERENCE; RNA STABILITY; RNA, MESSENGER; RNA, NEOPLASM; RNA-BINDING PROTEINS; TAMOXIFEN; UP-REGULATION;

EID: 85029127293     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M117.780973     Document Type: Article

References (68)

1. Tyson, J. J., Baumann, W. T., Chen, C., Verdugo, A., Tavassoly, I., Wang, Y., Weiner, L. M., and Clarke, R. (2011) Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat. Rev. Cancer 11, 523–532
2. Thomas, C., and Gustafsson, J. Å. (2011) The different roles of ER subtypes in cancer biology and therapy. Nat. Rev. Cancer 11, 597– 608
3. Ring, A., and Dowsett, M. (2004) Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11, 643– 658
4. Musgrove, E. A., and Sutherland, R. L. (2009) Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631– 643
5. Osborne, C. K., and Schiff, R. (2011) Mechanisms of endocrine resistance in breast cancer. Ann. Rev. Med. 62, 233–247
6. Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., and Schiff, R. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96, 926 –935
7. Dowsett, M. (2001) Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer 8, 191–195
8. Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A., Wong, J., Allred, D. C., Clark, G. M., and Schiff, R. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95, 353–361
9. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24, 85–95
10. Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., and Dowsett, M. (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23, 2469 –2476
11. Lipton, A., Leitzel, K., Ali, S. M., Demers, L., Harvey, H. A., Chaudri-Ross, H. A., Evans, D., Lang, R., Hackl, W., Hamer, P., and Carney, W. (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104, 257–263
12. Hurtado, A., Holmes, K. A., Geistlinger, T. R., Hutcheson, I. R., Nicholson, R. I., Brown, M., Jiang, J., Howat, W. J., Ali, S., and Carroll, J. S. (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663– 666
13. Zuo, T., Wang, L., Morrison, C., Chang, X., Zhang, H., Li, W., Liu, Y., Wang, Y., Liu, X., Chan M. W., Liu, J. Q., Love, R., Liu, C. G., Godfrey, V., Shen, R., et al. (2007) FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129, 1275–1286
14. Mehta, A., Trotta, C. R., and Peltz, S. W. (2006) Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells. Genes Dev. 20, 939 –953
15. Scott, G. K., Marx, C., Berger, C. E., Saunders, L. R., Verdin, E., Schäfer, S., Jung, M., and Benz, C. C. (2008) Destabilization of ERBB2 transcripts by targeting 3 untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol. Cancer Res. 6, 1250 –1258
16. Epis, M. R., Barker, A., Giles, K. M., Beveridge, D. J., and Leedman, P. J. (2011) The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331–3p in prostate cancer cells. J. Biol. Chem. 286, 41442– 41454
17. Scott, G. K., Goga, A., Bhaumik, D., Berger, C. E., Sullivan, C. S., and Benz, C. C. (2007) Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479 –1486
18. Filipowicz, W., Bhattacharyya, S. N., and Sonenberg, N. (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102–114
19. Esquela-Kerscher, A., and Slack, F. J. (2006) Oncomirs: microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259 –269
20. Kasinski, A. L., and Slack, F. J. (2011) Epigenetics and genetics: microRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11, 849 – 864
21. Liu, X. X., Li, X. J., Zhang, B., Liang, Y. J., Zhou, C. X., Cao, D. X., He, M., Chen, G. Q., He, J. R., and Zhao, Q. (2011) MicroRNA-26b is underex-pressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 585, 1363–1367
22. Maillot, G., Lacroix-Triki, M., Pierredon, S., Gratadou, L., Schmidt, S., Benes, V., Roche, H., Dalenc, F., Auboeuf, D., Millevoi, S., Bénès, V., Roché, H., Dalenc, F., Auboeuf, D., Millevoi, S., and Vagner, S. (2009) Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res. 69, 8332– 8340
23. Ebert, M. S., Neilson, J. R., and Sharp, P. A. (2007) MicroRNA sponges: competitiveinhibitorsofsmallRNAsinmammaliancells.Nat.Methods 4, 721–726
24. Bhat-Nakshatri, P., Wang, G., Collins, N. R., Thomson, M. J., Geistlinger, T. R., Carroll, J. S., Brown, M., Hammond, S., Srour, E. F., Liu, Y., and Nakshatri, H. (2009) Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 37, 4850 – 4861
25. Tan, S., Ding, K., Li, R., Zhang, W., Li, G., Kong, X., Qian, P., Lobie, P. E., and Zhu, T. (2014) Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2. Breast Cancer Res. 16, R40
26. Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., Jacob, S., and Majumder, S. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283, 29897–29903
27. Tan, S., Li, R., Ding, K., Lobie, P. E., and Zhu, T. (2011) miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 585, 2229 –2234
28. Jansen, M. P., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodríguez-González, F. G., Heine, A. A., Martens, J. W., Sleijfer, S., Foekens, J. A., and Berns, E. M. (2012) High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res. Treat. 133, 937–947
29. Kotta-Loizou, I., Vasilopoulos, S. N., Coutts, R. H., and Theocharis, S. (2016) Current evidence and future perspectives on HuR and breast cancer development, prognosis, and treatment. Neoplasia 18, 674 – 688
30. Brennan, C. M., and Steitz, J. A. (2001) HuR and mRNA stability. Cell. Mol. Life Sci. 58, 266 –277
31. Hostetter, C., Licata, L. A., Witkiewicz, A., Costantino, C. L., Yeo, C. J., Brody, J. R., and Keen, J. C. (2008) Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol. Ther. 7, 1496 –1506
32. Hostetter, C. L., Licata, L. A., and Keen, J. C. (2009) Timing is everything: order of administration of 5-aza 2 deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. Cancer Lett. 275, 178 –184
33. Mayr, C., and Bartel, D. P. (2009) Widespread shortening of 3UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673– 684
34. Di Giammartino, D. C., Nishida, K., and Manley, J. L. (2011) Mechanisms and consequences of alternative polyadenylation. Mol. Cell 43, 853– 866
35. Millevoi, S., and Vagner, S. (2010) Molecular mechanisms of eukary-otic pre-mRNA 3 end processing regulation. Nucleic Acids Res. 38, 2757–2774
36. Elkon, R., Ugalde, A. P., and Agami, R. (2013) Alternative cleavage and polyadenylation: extent, regulation and function. Nat. Rev. Genet. 14, 496–506
37. Proudfoot, N. J. (2011) Ending the message: poly(A) signals then and now. Genes Dev. 25, 1770 –1782
38. Jenal, M., Elkon, R., Loayza-Puch, F., van Haaften, G., Kühn, U., Menzies, F. M., Oude Vrielink, J. A., Bos, A. J., Drost, J., Rooijers, K., Rubinsztein, D. C., and Agami, R.(2012) The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 149, 538 –553
39. Masamha, C. P., Xia, Z., Yang, J., Albrecht, T. R., Li, M., Shyu, A. B., Li, W., and Wagner, E. J. (2014) CFIm25 links alternative polyadenylation to glio-blastoma tumour suppression. Nature 510, 412– 416
40. Xia, Z., Donehower, L. A., Cooper, T. A., Neilson, J. R., Wheeler, D. A., Wagner, E. J., and Li, W. (2014) Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3-UTR landscape across seven tumour types. Nat. Commun. 5, 5274
41. Jin, K., Park, S., Teo, W. W., Korangath, P., Cho, S. S., Yoshida, T., Gyo rffy, B., Goswami, C. P., Nakshatri, H., Cruz, L. A., Zhou, W., Ji, H., Su, Y., Ekram, M., Wu, Z., et al. (2015) HOXB7 Is an ER cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. Cancer Discov. 5, 944 –959
42. Lü, M., Ding, K., Zhang, G., Yin, M., Yao, G., Tian, H., Lian, J., Liu, L., Liang, M., Zhu, T., and Sun, F. (2015) MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRgamma. Sci. Rep. 5, 8735
43. Arpino, G., Wiechmann, L., Osborne, C. K., and Schiff, R. (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 29, 217–233
44. Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., and Osborne, C. K. (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10, 331S–336S
45. Egeland, N. G., Lunde, S., Jonsdottir, K., Lende, T. H., Cronin-Fenton, D., Gilje, B., Janssen, E. A., and Søiland, H. (2015) The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients. Int. J. Mol. Sci. 16, 24243–24275
46. Wong, C. F., and Tellam, R. L. (2008) MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J. Biol. Chem. 283, 9836 –9843
47. Krüger, J., and Rehmsmeier, M. (2006) RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34, W451–W454
48. Heinonen, M., Bono, P., Narko, K., Chang, S. H., Lundin, J., Joensuu, H., Furneaux, H., Hla, T., Haglund, C., and Ristimäki, A. (2005) Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 65, 2157–2161
49. Denkert, C., Weichert, W., Winzer, K. J., Müller, B. M., Noske, A., Nies-porek, S., Kristiansen, G., Guski, H., Dietel, M., and Hauptmann, S. (2004) Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin. Cancer Res. 10, 5580 –5586
50. Heinonen, M., Fagerholm, R., Aaltonen, K., Kilpivaara, O., Aittomäki, K., Blomqvist, C., Heikkila, P., Haglund, C., Nevanlinna, H., and Ristimäki, A. (2007) Prognostic role of HuR in hereditary breast cancer. Clin. Cancer Res. 13, 6959 – 6963
51. Zhuang, R., Rao, J. N., Zou, T., Liu, L., Xiao, L., Cao, S., Hansraj, N. Z., Gorospe, M., and Wang, J. Y. (2013) miR-195 competes with HuR to modulate stim1 mRNA stability and regulate cell migration. Nucleic Acids Res. 41, 7905–7919
52. Tominaga, K., Srikantan, S., Lee, E. K., Subaran, S. S., Martindale, J. L., Abdelmohsen, K., and Gorospe, M. (2011) Competitive regulation of nucleolin expression by HuR and miR-494. Mol. Cell. Biol. 31, 4219 – 4231
53. Borg, A., Baldetorp, B., Fernö, M., Killander, D., Olsson, H., Rydén, S., and Sigurdsson, H. (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81, 137–144
54. Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M., Harper, M. E., Barrow, D., Wakeling, A. E., and Nicholson, R. I. (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032–1044
55. Chu, I., Blackwell, K., Chen, S., and Slingerland, J. (2005) The dual ErbB1/ ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 65, 18 –25
56. Dowsett, M., Harper-Wynne, C., Boeddinghaus, I., Salter, J., Hills, M., Dixon, M., Ebbs, S., Gui, G., Sacks, N., and Smith, I. (2001) HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 61, 8452– 8458
57. Kang, H., Kim, C., Lee, H., Kim, W., and Lee, E. K. (2013) Post-transcriptional controls by ribonucleoprotein complexes in the acquisition of drug resistance. Int. J. Mol. Sci. 14, 17204 –17220
58. Yuan, Z., Sanders, A. J., Ye, L., and Jiang, W. G. (2010) HuR, a key post-transcriptional regulator, and its implication in progression of breast cancer. Histol. Histopathol. 25, 1331–1340
59. Pryzbylkowski, P., Obajimi, O., and Keen, J. C. (2008) Trichostatin A and 5 aza-2 deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res. Treat. 111, 15–25
60. Erson-Bensan, A. E., and Can, T. (2016) Alternative polyadenylation: another foe in cancer. Mol. Cancer Res. 14, 507–517
61. Mansfield, K. D., and Keene, J. D. (2012) Neuron-specific ELAV/Hu proteins suppress HuR mRNA during neuronal differentiation by alternative polyadenylation. Nucleic Acids Res. 40, 2734 –2746
62. Al-Ahmadi, W., Al-Ghamdi, M., Al-Haj, L., Al-Saif, M., and Khabar, K. S. (2009) Alternative polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich elements and auto-regulation. Nucleic Acids Res. 37, 3612–3624
63. Al-Ahmadi, W., Al-Ghamdi, M., Al-Souhibani, N., and Khabar, K. S. (2013) miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J. Pathol. 230, 28 –38
64. Guo, X., Wu, Y., and Hartley, R. S. (2009) MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol. 6, 575–583
65. Dai, W., Zhang, G., and Makeyev, E. V. (2012) RNA-binding protein HuR autoregulates its expression by promoting alternative polyadenylation site usage. Nucleic Acids Res. 40, 787– 800
66. Li, C., Feng, Y., Coukos, G., and Zhang, L. (2009) Therapeutic microRNA strategies in human cancer. AAPS J. 11, 747–757
67. Orom, U. A., and Lund, A. H. (2007) Isolation of microRNA targets using biotinylated synthetic microRNAs. Methods 43, 162–165
68. Li, S., Zhu, J., Fu, H., Wan, J., Hu, Z., Liu, S., Li, J., Tie, Y., Xing, R., Zhu, J., Sun, Z., and Zheng, X. (2012) Hepato-specific microRNA-122 facilitates accumulation of newly synthesized miRNA through regulating PRKRA. Nucleic Acids Res. 40, 884 – 891